Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses New PI3K-Delta Inhibitor Umbralisib: Greater Then 50% Response Rate, Remissions Lasting For Over A Year.
New PI3K-Delta Inhibitor Umbralisib: Greater Then 50% Response Rate, Remissions Lasting For Over A Year
